Skip to main content
Premium Trial:

Request an Annual Quote

Abbott Labs Invests $20 Million in Genset in Pharmacogenomics Deal

Premium

ABBOTT PARK, Ill.--Abbott Laboratories here will invest $20 million in Paris-based genomics company Genset and pay as much as $22.5 million more in research funding over the next 18 months as part of what the companies call a "pharmacogenomics analysis" agreement aimed at helping to customize the use of pharmaceuticals for specific subgroups of patients based on genetic differences. The investment will come in the form of a $10 million up-front payment plus another $10 million upon exercise of a put option by Genset during the second year. Abbott will gain almost a 5 percent stake in Genset.

Under terms of the deal, Genset will develop a high-density, biallelic marker map of a human genome and identify markers and genes associated with drug metabolism. Abbott will then develop, produce, and market diagnostic systems derived from the research to test patient response to specific drugs. The two companies will share revenues from milestone and royalty payments based on their respective research contributions to products.

Filed under

The Scan

Another Resignation

According to the Wall Street Journal, a third advisory panel member has resigned following the US Food and Drug Administration's approval of an Alzheimer's disease drug.

Novavax Finds Its Vaccine Effective

Reuters reports Novavax's SARS-CoV-2 vaccine is more than 90 percent effective in preventing COVID-19.

Can't Be Used

The US Food and Drug Administration says millions of vaccine doses made at an embattled manufacturing facility cannot be used, the New York Times reports.

PLOS Papers on Frozen Shoulder GWAS, Epstein-Barr Effects on Immune Cell Epigenetics, More

In PLOS this week: genome-wide association study of frozen shoulder, epigenetic patterns of Epstein-Barr-infected B lymphocyte cells, and more.